We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

April 22, 2022

Sprint: Virtual Care for T2-Diabetes and Obesity

Commentary
HealthXL Team & HealthXL Community
&

In our two-part HealthXL Sprint meetings, we connect senior leaders across our community to solve health challenges. 

In our most recent sprint, we discussed virtual care for type-2 diabetes and obesity, here are  key takeaways. 

Experts included: Armin Furtwaengler (Global Medical Lead Innovation Scouting, Corporate Division Medicine at Boehringer Ingelheim), Cathy Zaremba (Director of Product Marketing at BrightInsight), Chris Wasden (Head of Pharma Speciality Solutions & Corporate Strategy at Happify Health), Daphne Petrich (Senior Business Development Manager at HelloBetter), Fredrik Debong (Co-founder and CPO at hi.health), Jim Howard (CEO at Readout Health), Kasparas Aleknavičius (Head of Medical Affairs at Kilo Health), Kathleen Wright (Founder at Second Brain Healthcare), Lee Shapiro (Managing Partner at 7wire Ventures), Meaghan Schedel (Consultant at HealthXL),  Mike Pace (CEO and founder at PalmHealth.co), Naomi Parrella (Medical Director, Rush Center for Weight Loss and Lifestyle Medicine at Rush University Medical Center), Piotr Sokolowski (Chief MedTech Strategist at S3 Connected Health), Stephen Egan (Director at Redicare), Thomas Foley (Chief Growth Officer at GenieMD)

*All opinions are participants’ own and do not reflect the stance of their respective employers.

5 Key Recommendations: 

Diabetes prevention needs to be personalized and should start earlier: Even with increased community education efforts about diet, exercise, and prevention, there is a growth in the rate of type 2 diabetes. Diabetes is multi-faceted and prevention programs need to be personalized for disease states and demographics. A radical transformation of behaviors is a long journey and starts with the rejection of factors such as a carbohydrate rich diet, sedentary lifestyle, and poor sleep. For many people, that transformation is about building an awareness of the body’s signals and knowledge of how to respond in effective ways, earlier. Solutions need to contribute to an environment where better behavior is easy. There needs to be reminders of the progress being made that make the solution rewarding and engaging rather than intrusive. 

Solutions must interrupt the cycle of poor habits: Anxiety and depression may contribute to the underlying reasons behind poor eating habits that lead to obesity. However, while obesity is often exacerbated by mood disorders and their treatments, it is also a marker of an imbalance in the body and depression and anxiety can be another manifestation of the “lack of health”. The hypothalamic-pituitary-adrenal (HPA) axis is off balance. This presents a chicken and egg scenario between the two factors and can create a damaging cycle. The key is to interrupt that cycle. While the importance of mental health is clear, we may also want to consider focusing on ways to effectively begin treatment in order to reverse the course. One great start is working on beliefs, understanding, and mindset. Obesity, T2-Diabetes, and mental health are all connected, but treating mental health will not necessarily allow the cardiometabolic dysfunction to resolve on its own. 

The pharma route to market is challenging for diabetes solutions: When an independent  solution gets acquired by a pharma/medtech company, as in the case of mySugr by Roche, the risk is that other manufacturers then stop working with the group. Internists don’t want to have a different platform for each product, yet the patients are first and foremost individuals and need choice. Patients want a digital therapeutic (DTx) that is drug agnostic and can work across all medications within a therapeutic area as they will likely change their therapy over their disease journey. Solution adoption needs to become easier and more streamlined, a unified data stream made available and easily integrated into existing management platforms. Pharma companies are also deprioritizing diabetes from their portfolios. Multiple generic drugs on the market make the space less profitable for pharma. The willingness to invest in digital therapies that address this space is not a high priority or part of a long-term strategy unless aligned with a specific initiative like a digital biomarker to drug development. A more productive route to market may be through partnering with medical device companies that are concentrating their efforts on easing the measurement of blood glucose levels (e.g., Dexcom and Abbott).

Consumers will pay for diabetes remission programs if they have good clinical outcomes for “reasonable effort”: The Direct-to-consumer (D2C) model empowers people who want to be empowered as opposed to being influenced by a pharma company or a health system they don’t frequently visit. Yet in countries with a public healthcare system, a patient paying for a solution is remarkable. D2C is scalable when it comes to growth, but that does not necessarily equate to financial sustainability. D2C can be a stepping stone to other routes to market. If a solution can build a focus on wellness and behavior change that people stick with, that could build the foundation for a solution to enter into partnerships and platform plays with healthcare systems. The solutions can’t be too daunting or seem impossible to stick with. Consumers need to believe it’s possible and worth it to justify the effort and cost. The cost of patient acquisition through social media can easily be $200 or more. If the price point of a D2C solution is $600, companies are spending as much as a third on the cost of acquisition. D2C solutions might need to start at a higher price point or be pursued in parallel with other paths to market.  

Providers and health systems can provide credibility for your solution: Word of mouth can help a company scale rapidly. A physician referral can build trust and belief in a solution. Paying consumers are interested in changing behaviors, but don’t know what they want or need to get there. But mainly the drive to adopt a solution lies in looking for a simpler way to get a good outcome, not necessarily the best outcome. Patients and providers need the right language to have conversations efficiently and in a way that doesn't burden the provider. Adoption needs to be simple for the clinician and if a solution can quickly deliver results the provider could become an advocate. For T2-diabetes, providers will also be more interested in solutions with actual personalized data (biomarkers) vs. those that are behavior-heavy, personalized light. Health systems with a long term relationship with a consumer can create better outcomes by focusing on prevention - this includes reduction in the risk of T2-diabetes. For countries where there is a national health system, these efforts may take hold more quickly than in a fragmented system like the US. 

Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Community for access to polls and summaries from all of our meetings. 

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Reimbursement in the US - PBMs as Coverage Scale Catalysts

10th August @ 10:45AM EDT

Are you a DTx or Pharma company seeking wide-spread reimbursement of a DTx product in the US? Join this Masterclass led by Mike Pace to learn more about this topic and share your experiences with others working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Value, Cost and Pricing in Regulated Digital Health Solutions

11th August @ 10:45AM EDT

Digital Health solutions are top of mind for biopharma companies in 2022, and Software as Medical Device (SaMD) is a crucial cornerstone for top-tier companies. Join this Masterclass led by BrightInsight to dive deeper into this topic and discuss this further with your peers working in this space.

Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight
Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Payers Partnerships for DTx

17th August @ 10:45AM EDT

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Join this meeting to discuss this topic further and share your experiences with others working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Reimbursement in the US - PBMs as Coverage Scale Catalysts

10th August @ 10:45AM EDT

Are you a DTx or Pharma company seeking wide-spread reimbursement of a DTx product in the US? Join this Masterclass led by Mike Pace to learn more about this topic and share your experiences with others working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Value, Cost and Pricing in Regulated Digital Health Solutions

11th August @ 10:45AM EDT

Digital Health solutions are top of mind for biopharma companies in 2022, and Software as Medical Device (SaMD) is a crucial cornerstone for top-tier companies. Join this Masterclass led by BrightInsight to dive deeper into this topic and discuss this further with your peers working in this space.

Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight
Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight

Executive 1-2-1 with the HealthXL Digital Health Community

15th August @11AM EDT

Do you want to network with other innovators and leaders in digital health? Are you looking to identify potential partners? Join us for the new HealthXL style of virtual speed networking and meet other members working in this space!

Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.